Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8378512 | 0.65 | CYP1A2 (0.41) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL27343523 | 0.65 | GRM6 (0.37) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL9541767 | 0.65 | — | — | |
| SCHEMBL29733309 | 0.63 | CYP1A2 (0.46) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL11564617 | 0.63 | CYP1A2 (0.46) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL1417449 | 0.63 | NOS1 (0.43) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL27748632 | 0.62 | CYP1A2 (0.49) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL8763542 | 0.62 | CYP1A2 (0.38) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL999293 | 0.61 | CYP1A2 (0.47) | CYP1A2GABRA5GABRB2HSD17B10MEN1 | |
| SCHEMBL6541762 | 0.59 | CYP1A2 (0.39) | CYP1A2GABRA5GABRB2HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090631-B2 | Process for purifying cefotiam hydrochloride | HAINAN LINGKANG PHARMACEUTICAL CO., LTD. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-20140011994-A1 | NOVEL PROCESS FOR PURIFYING CEFOTIAM HYDROCHLORIDE | HAINANLINGKANG PHARMACEUTICAL CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011994-A1 | NOVEL PROCESS FOR PURIFYING CEFOTIAM HYDROCHLORIDE | NOTUM, SAMM50, MGAM | CYP1A2 1136/4885GABRA5 3172/4885GABRB2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.